The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Klein, David J ^a   Foster, Debra ^b   Schorr, Christa A ^c   Kazempour, Kazem ^d   Walker, Paul M ^b   Dellinger, R P ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Spectral Diagnostics Inc   (Canada)

^c Department of Anesthesiology   (United States)

^d Amarex Clinical Research   (United States)

Author keywords

Endotoxemia; Endotoxin; Hemoperfusion; Polymyxin B; Septic shock; Theragnostics

Indexed keywords

ADRENALIN; DOPAMINE; ENDOTOXIN; NORADRENALIN; PHENYLEPHRINE; PLACEBO; POLYMYXIN B; VASOPRESSIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; ENDOTOXEMIA; FLUID RESUSCITATION; HEMOPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; ORGAN DYSFUNCTION SCORE; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; METHODOLOGY; SHOCK, SEPTIC;

ADULT; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; ENDOTOXEMIA; HEMOPERFUSION; HUMANS; POLYMYXIN B; RESEARCH DESIGN; SHOCK, SEPTIC;

EID: 84903130991     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-218     Document Type: Article

References (32)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
3. Suffredini AF, Munford RS. Novel therapies for septic shock over the past 4 decades. JAMA 2011, 306:194-199.
4. Angus DC, Mira JP, Vincent JL. Improving clinical trials in the critically ill. Crit Care Med 2010, 38:527-532. 10.1097/CCM.0b013e3181c0259d, 19851096.
5. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A. Diagnostic and prognostic mplications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 190:527-534. 10.1086/422254, 15243928.
6. Opal SM, Cohen J. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?. Crit Care Med 1999, 27:1608-1616. 10.1097/00003246-199908000-00039, 10470773.
7. Klein DJ, Derzko A, Foster D, Seely AJ, Brunet F, Romaschin AD, Marshall JC. Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock 2007, 28:524-529.
8. Opal SM, Gluck T. Endotoxin as a drug target. Crit Care Med 2003, 31(1 Suppl):S57-S64.
9. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982, 307:1225-1230. 10.1056/NEJM198211113072001, 6752708.
10. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, Hollender E, Immerman R, Pfaller M, Sheetz C, Jebson P, Houston A, Rehak D, Empson P, Ireland J, Narain S, Rashkin JE, Jacobs RA, Octavio J, Coleman R, Kenyon VS, Yangco BG, Toney JF, Edwards J, Crislip M, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991, 266:1097-1102. 10.1001/jama.1991.03470080067031, 1865542.
11. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, Allen E, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, . and the HA-1A Sepsis Study Group Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991, 324:429-436. 10.1056/NEJM199102143240701, 1988827, and the HA-1A Sepsis Study Group.
12. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994, 121:1-5. 10.7326/0003-4819-121-1-199407010-00001, 8198341.
13. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000, 283:1723-1730. 10.1001/jama.283.13.1723, 10755499.
14. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Critl Care Med 2010, 38:1685-1694.
15. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, . for the ACCESS Study Group Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013, 309:1154-1162. 10.1001/jama.2013.2194, 23512062, for the ACCESS Study Group.
16. Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J, . for the Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009, 37:2929-2938. 10.1097/CCM.0b013e3181b0266c, 19770753, for the Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators.
17. Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2011, 11:65-71. 10.1016/S1473-3099(10)70220-6, 21183148.
18. Cruz D, Perazella M, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri V, Ronco C. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007, 11:1-12.
19. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301:2445-2452. 10.1001/jama.2009.856, 19531784.
20. Kellum JA, Uchino S. International differences in the treatment of sepsis: are they justified?. JAMA 2009, 301:2496-2497. 10.1001/jama.2009.850, 19531792.
21. Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, Parrillo JE, Dellinger RP. Multi-center study of early lactate clearance as a determinant of survival in patients with presumed Sspsis. Shock 2008, 32:35-39.
22. Cook R, Cook D, Tilley J, Lee K, Marshall J, . Canadian Critical Care Trials Group Multiple organ dysfunction: baseline and serial component scores. Crit Care Med 2001, 29:2046-2050. 10.1097/00003246-200111000-00002, 11700393, Canadian Critical Care Trials Group.
23. Warnock DG. Towards a definition and classification of acute kidney injury. J Am Soc Nephrol 2005, 16:3149-3150. 10.1681/ASN.2005090934, 16207828.
24. Levy MM, ellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC, . Surviving Sepsis Campaign The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010, 38:367-374. 10.1097/CCM.0b013e3181cb0cdc, 20035219, Surviving Sepsis Campaign.
25. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, . International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437, International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine.
26. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, . Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup.
27. Marshall JC, Walker PM, Foster DM, Harris D, Ribeiro M, Paice J, Romaschin AD, Derzko AN. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 2002, 6:342-348. 10.1186/cc1522, 125316, 12225611.
28. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556. 10.2307/2530245, 497341.
29. Agresti A. Categorical Data Analysis 1990, New York: Wiley.
30. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997, 25:372-374. 10.1097/00003246-199702000-00029, 9034279.
31. Fdr P, Courtine E, Cariou A, Mira J-P. Toward theragnostics. Crit Care Med 2009, 37:S50-S58. 10.1097/CCM.0b013e3181921349, 19104225.
32. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med 1999, 341:992-996. 10.1056/NEJM199909233411312, 10498498.